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A Role for Epigenetics in Psoriasis: 
Methylated Cytosine–Guanine Sites 
Differentiate Lesional from Nonlesional 
Skin and from Normal Skin
Johann E. Gudjonsson1 and Gerald Krueger2
DNA methylation is one of several epigenetic mechanisms that can lead to stable 
and heritable changes in gene expression without changing the underlying DNA 
sequence. In this issue, Roberson et al. demonstrate that lesional skin in psoriasis is 
accompanied by changes in DNA methylation, which revert back to baseline with 
treatment, indicating that DNA methylation in psoriasis is dynamic.
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Epigenetic information can be trans-
mitted by several mechanisms, including 
gene silencing by DNA methylation, 
posttranslational modification of histone 
proteins and noncoding RNAs, and 
mitotic retention of regulatory machin-
ery at target gene loci for activation and 
repression (Zaidi et al., 2011). DNA 
methylation is an established epigen-
etic mechanism for both transient and 
irreversible transcriptional silencing 
(Zaidi et al., 2011), and it involves direct 
covalent modification of nucleotides, 
primarily cytosine in cytosine–guanine 
(CpG) dinucleotide sequences. Although 
methylation preferentially represses 
expression of genes, it can occasionally 
be activating when it prevents binding 
or limits expression of transcriptional 
repressors. Furthermore, CpG methyla-
tion can guide the placement and main-
tenance of other epigenetic tags such as 
posttranslational modifications of core 
histone proteins that package DNA into 
nucleosomal particles. Histones can be 
posttranslationally modified by several 
different processes, including phosphor-
ylation, ubiquitination, acetylation, and 
methylation. It is thought that different 
combinations of histone modifications 
regulate chromatin structure and tran-
scriptional status by altering the binding 
affinity of proteins that mediate transcrip-
tional activity and by influencing higher-
order interactions between nucleosomes 
and chromatin fiber organization (Zaidi 
et al., 2011) (Figure 1). Thus, the epigen-
etic modifications at the DNA, nucleoso-
mal, and chromosomal level affect gene 
expression, and ultimately phenotypes, 
by providing differential access to the 
underlying genetic information. Other 
epigenetic processes involve noncoding 
RNAs, which, through direct base pair-
ing with target DNA or RNA, can lead 
to transcriptional inhibition (Zaidi et al., 
2011) and mitotic retention of gene reg-
ulatory machinery (Zaidi et al., 2011).
The full range of epigenetic modifi-
cations is currently unknown, but it is 
potentially enormous, considering that 
the diploid human epigenome contains 
more than 108 cytosine nucleotides (of 
which more than 107 are CpGs) and 
more than 108 histone tails that all can 
Psoriasis is a chronic inflammatory 
disease associated with complex inter-
actions between genetics and the 
environment that are still not well 
defined. Part of this interaction can 
occur through a mechanism called epi-
genetics, a process that leads to stable 
and heritable changes in gene expres-
sion without change in the underlying 
DNA sequences. Epigenetic mecha-
nisms are involved in processes such as 
parental imprinting, whereby a single 
allele is differentially expressed depend-
ing on the sex of the parent transmitting 
the allele, and X-chromosome inacti-
vation, which leads to transcriptional 
silencing of a large percentage of genes 
on one X chromosome in females. Over 
the past two decades, a few publications 
have addressed the potential role of epi-
genetics on the heritability of psoriasis, 
including the preferential transmission 
of psoriatic arthritis from the paternal 
side (Karason et al., 2003; Rahman et 
al., 1999) and increased birth weight in 
children of fathers with psoriasis (Traupe 
et al., 1992). However, the genes or 
mechanisms involved remain uncertain.
Of even greater importance is the 
observation that maintenance of cellular 
differentiation may be considered an 
epigenetic phenomenon. In this respect, 
various tissues have distinct functions 
with disparate, yet stable, profiles of 
gene expression despite having identi-
cal genotypes; this phenomenon would 
explain how a phenotype can be passed 
from one cell to its daughter cells. These 
processes can also be modified by exog-
enous influences, and they can con-
tribute to or result from environmental 
alterations in phenotype or pathology 
(Handy et al., 2011). This can be of spe-
cial importance in psoriasis because 
one of its distinctive features is marked 
thickening of the epidermis, reflecting 
altered differentiation and increased pro-
liferation of keratinocytes. Such changes 
in psoriatic skin have been likened to 
wound healing, and they are accompa-
nied by marked changes in global gene 
expression, representing an alternative 
pathway of keratinocyte differentia-
tion that has been termed “regenerative 
maturation” and is activated in response 
to immunologic stimulation. The mecha-
nisms by which this occurs are unknown. 
Thus, it should not come as a surprise 
if changes in lesional psoriatic skin are 
accompanied by epigenetic changes.
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potentially vary (Rakyan et al., 2011). 
Approximately 70% of human genes 
are linked to promoter CpG islands. 
Only recently have epigenomic pro-
filing technologies reached the stage 
at which large-scale epigenome-wide 
association studies of DNA methylation 
are feasible (Rakyan et al., 2011), and, 
although other epigenetic mechanisms 
may be just as important, they are not yet 
as amenable to high-throughput process-
ing (Rakyan et al., 2011). In addition, an 
epigenomic equivalent of the HapMap 
project (a reference for the level of nor-
mal epigenetic variation that exists in 
human populations) is lacking.
Roberson et al. (2012, this issue) are 
the first to study global CpG methylation 
in psoriasis. They analyzed the meth-
ylation status of more than 27,000 CpG 
sites in skin samples from lesions and 
nonlesional skin of patients with psoria-
sis and skin of healthy controls. Despite 
being limited by a small study cohort 
and relatively low overall coverage of 
CpG sites, 1,100 differentially methyl-
ated CpG sites were detected between 
psoriatic and control skin. Twelve CpG 
sites mapped to the epidermal differ-
entiation complex (which, as the name 
implies, contains large numbers of genes 
involved in epidermal function and dif-
ferentiation). There was a decrease in 
methylation at these sites, and they 
mapped close to genes that are highly 
upregulated in psoriasis. The investiga-
tors were able to use 50 of the top differ-
entially methylated sites to separate skin 
from patients with psoriasis from that of 
controls. Interestingly, with anti–tumor 
necrosis factor treatment, these methyla-
tion changes reverted back to baseline. 
Although this study is limited to CpG 
methylation, the findings provide novel 
insights into the epigenetic processes 
involved in psoriasis pathogenesis, and 
they suggest that these changes occur 
primarily in lesional keratinocytes and 
that they are transient.
What are the implications of this 
information? Several issues can arise 
from epigenetic data. As mentioned 
above, cellular differentiation may be 
considered an epigenetic phenomenon, 
in which each tissue has a distinct epi-
genetic profile. It is important to keep 
tissue heterogeneity in mind if disease-
associated variations are restricted to 
a small proportion of cells in a tissue, 
in which case the variation may not be 
detectable. The disease state itself can 
alter the composition of cell types in a 
tissue, as is the case with psoriasis, in 
which infiltration by subsets of inflam-
matory cells and increased growth of 
blood vessels occur. Therefore, epi-
genetic differences that are measured 
between cases and controls may reflect 
differences in cell-type composition only 
and not be true epigenetic differences.
Another challenge is the state of 
tissue or cellular differentiation. In pso-
riasis there is altered maturation and 
proliferation of keratinocytes, a process 
that has been likened to wound heal-
ing and is likely to be tightly controlled 
and accompanied by changes in the 
epi genome because it represents an 
alternative pathway of differentiation. 
Finally, epigenetic variation can cause 
disease or arise as a consequence of 
disease. Distinguishing between these 
two possibilities, although not straight-
forward, is essential because it may help 
to elucidate the functional role of the 
disease-associated variation and its diag-
nostic and therapeutic utilities (Rakyan 
et al., 2011). This differentiation could 
be achieved by determining whether 
the variation is present prior to any overt 
signs of disease. The intermediate meth-
ylation detected in nonlesional psori-
atic skin in the study by Roberson et al. 
(2012) could be interpreted to suggest 
such predisposition. However, definitive 
conclusions may be premature because 
nonlesional psoriatic skin is in a “preac-
tivated” state (Gudjonsson et al., 2009), 
and it is unclear whether this is due 
to circulating inflammatory mediators 
from active skin lesions or an underlying 
genetic predisposition.
Another challenge is determining the 
mechanisms that regulate CpG methyla-
tion and their importance in skin. A fam-
ily of DNA methyltransferase enzymes 
(DNMTs) is involved in de novo DNA 
methylation and its maintenance. Three 
catalytically active DNMTs are involved 
in DNA methylation: DNMT3A and 
DNMT3B, which are linked mainly to 
DNA methylation in early development 
(Khavari et al., 2010); and the ubiquitously 
expressed DNMT1, which is thought to be 
responsible primarily for maintaining cel-
lular levels of CpG methylation. DNMT1 
Figure 1. DNA methylation and histone modifications. DNA methylation and histone modifications 
are two of the best-defined epigenetic mechanisms of gene expression, others being RNA-mediated 
gene silencing and mitotic retention of transcriptional regulatory machinery (not shown). Chromosomal 
DNA is packaged around histone cores to form nucleosomes. A nucleosome has 147 base pairs 
of DNA associated with an octomeric core of histone proteins. Nucleosome spacing (panel a, top) 
in active chromatin is an open structure that is accessible to nuclear factors and is maintained in 
part by posttranslational modification of histone tails, including lysine acetylation and specific 
lysine methylation. Cytosine–guanine (CpG) dinucleotides are distributed unequally throughout 
chromosomal DNA and may be concentrated in regions called CpG islands that typically overlap with 
gene promoters. Methylation of cytosine in CpG dinucleotides is associated with inactive, condensed 
states of the chromosome (panel a, bottom). This inactive state is also maintained by specific histone 
lysine modifications. DNA methylation involves attachment of a methyl group to the C5 position of 
cytosine residues in CpG dinucleotide sequences and typically results in silencing of gene transcription 
(panel b, top). Histone modifications occur posttranslationally, and different combination changes 
(phosphorylation, ubiquitination, acetylation, and methylation) may regulate chromatin structure and 
transcriptional status (Handy et al., 2011; panel b, bottom). Adapted with permission from Handy et al. 
(2011) and Zaidi et al. (2011).
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has been shown to be essential for epi-
dermal progenitor cell function and 
is enriched in undifferentiated cells, 
where it suppresses differentiation and 
maintains proliferative properties (Sen 
et al., 2010). Interestingly, a proportion 
of genes repressed during differentiation 
become methylated de novo, and some 
genes lose methylation during this process. 
Thus, DNA methylation is a dynamic pro-
cess that occurs during epidermal differ-
entiation (Sen et al., 2010). In agreement 
with the observed aberrant keratinocyte 
differentiation and hyper proliferation, 
we were able to demonstrate upregulation 
of DNMT1 in psoriasis by approximately 
1.5-fold (Gudjonsson, unpublished obser-
vation). Interestingly, proinflammatory 
cytokines such as interleukin-6, which 
is increased in psoriasis, can induce the 
expression and activity of DNMT1 (Hodge 
et al., 2001). Much less is known about 
the regulation of demethylases in the epi-
dermis; this will be an interesting area for 
future research.
We have barely scratched the surface 
of the role of epigenetics in the skin. As 
technology progresses, and with it our 
ability to determine other types of epi-
genetic changes, we predict that a more 
complete view of the mechanisms oper-
ating in psoriatic plaques will emerge. 
Taken together, data from Roberson et 
al. (2012) indicate that DNA methyla-
tion in psoriasis is a dynamic process, 
influenced—and possibly even driven 
entirely—by the cytokine environment. 
These changes in the epigenome are 
likely to have a major role in orches-
trating the altered differentiation and 
proliferation observed in psoriatic 
lesions. Characterizing the mechanisms 
involved and the consequences of these 
changes are exciting avenues for future 
research.
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The Three Dimensions of 
Functional T-Cell Tolerance: 
From Research to Practice
Christian Hünefeld1, Markus Mezger2, Michael Röcken3,4 
and Martin Röcken1
In this issue, Paek et al. describe two phenomena. First, they show that 
intermediate concentrations of a “transgenic” autoantigen may cause a 
lichen planus–like autoimmune disease. Second, and more importantly, they 
show that high doses of peptide antigen suppress the expression of the T-cell 
receptor and coreceptors, particularly CD8, and that this suppression improves 
this T-cell-mediated, destructive inflammatory skin disease that is similar to 
erosive lichen planus.
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T-cell tolerance resulting from recep-
tor downregulation was first described 
20 years ago (Schönrich et al., 1991). 
The long road between recognizing 
Clinical Implications
•  DNA methylation is one of several epigenetic mechanisms that can lead 
to stable and heritable changes in gene expression without changing 
the underlying DNA sequence.
•  Lesional skin in psoriasis is accompanied by changes in DNA 
methylation.
•  Changes in DNA methylation revert to baseline with treatment, 
indicating that in psoriasis it is dynamic.
